前列腺癌症市場:KOL的洞察

本報告提供全球前列腺癌症市場相關調查，提供市場概要，以及已上市治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

現在及未來的治療流程

調查目的

下一代雄激素受體抑制劑

• 已上市藥物
  • Xtandi (enzalutamide; Astellas Pharma/Pfizer)
  • Erleada (apalutamide; Johnson & Johnson)
  • Nubeqa (darolutamide; Bayer/Orion)

新製劑雄激素消除療法

• 已上市藥物
  • Orgovyx (relugolix; Sumitomo Pharma/Takeda)

PARP抑制劑

• 已上市藥物
  • Rubraca (rucaparib; Pharmaand GmbH)
  • Lynparza (olaparib; AstraZeneca)
  • Talzenna (talazoparib; Pfizer)
• 開發平台藥物
  • Saruparib (AstraZeneca)

PD-1/PD-L1查核點抑制劑

• 開發平台藥物
  • Tecentriq (atezolizumab; Genentech/Roche)
  • Keytruda (pembrolizumab; Merck & Co.)

放射線治療

• 已上市藥物
  • Xofigo (radium-223 dichloride; Bayer)
  • Pluvicto (Lutetium-177 PSMA 617; Novartis)
• 開發平台藥物
  • [Lu-177]-PNT2002 (Lantheus/POINT Biopharma)

AKT抑制劑

• 開發平台藥物
  • Truqap (capivasertib; AstraZeneca)

週期蛋白依賴型激梅抑制劑

• 開發平台藥物
  • Verzenio (abemaciclib; Eli Lilly and Company)

今後的治療趨勢

附錄

Delve into the evolving landscape of prostate cancer treatment with insights from 12 key opinion leaders. This report explores the future of therapies like Xtandi, Erleada, and Orgovyx, the impact of PARP inhibitors, and the potential of novel treatments. Understand the challenges and opportunities in addressing unmet needs and the role of AI in advancing care.

Key questions answered:

• How is the use of Xtandi expected to evolve in the next three to five years?
• What is the clinical experience with Erleada, and how significant is its Phase III PROTEUS study?
• Can Orgovyx challenge conventional ADTs in clinical practice?
• How are PARP inhibitors impacting the treatment paradigm for prostate cancer
• What role might immune checkpoint inhibitors play in prostate cancer treatment?
• How significant is the approval of Pluvicto for metastatic prostate cancer, and what are its benefits over Xofigo?

Key brands covered in this report:

Companies:

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Next-generation androgen receptor inhibitors

• Marketed drugs
  • Xtandi (enzalutamide; Astellas Pharma/Pfizer)
  • Erleada (apalutamide; Johnson & Johnson)
  • Nubeqa (darolutamide; Bayer/Orion)

Novel formulation androgen-deprivation therapies

• Marketed drugs
  • Orgovyx (relugolix; Sumitomo Pharma/Takeda)

PARP inhibitors

• Marketed drugs
  • Rubraca (rucaparib; Pharmaand GmbH)
  • Lynparza (olaparib; AstraZeneca)
  • Talzenna (talazoparib; Pfizer)
• Pipeline drugs
  • Saruparib (AstraZeneca)

PD-1/PD-L1 checkpoint inhibitors

• Pipeline drugs
  • Tecentriq (atezolizumab; Genentech/Roche)
  • Keytruda (pembrolizumab; Merck & Co.)

Radiation-based therapies

• Marketed drugs
  • Xofigo (radium-223 dichloride; Bayer)
  • Pluvicto (Lutetium-177 PSMA 617; Novartis)
• Pipeline drugs
  • [Lu-177]-PNT2002 (Lantheus/POINT Biopharma)

AKT inhibitors

• Pipeline drugs
  • Truqap (capivasertib; AstraZeneca)

Cyclin-dependent kinase inhibitors

• Pipeline drugs
  • Verzenio (abemaciclib; Eli Lilly and Company)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe